Literature DB >> 25617040

Anxiety and substance use disorders: co-occurrence and clinical issues.

Florence Vorspan1, Wajdi Mehtelli, Gaël Dupuy, Vanessa Bloch, Jean-Pierre Lépine.   

Abstract

The co-occurrence of substance use disorders (SUDs) and anxiety disorders has been now well established. This association is frequent and can be explained by three models: the shared vulnerability factors model, the self-medication model, and the substance-induced model. General population epidemiological studies provide strong evidence of the frequency of the association for the most used substances: tobacco, alcohol, cannabis, and to a lesser extent sedatives, opiates, and cocaine. For substances that are less commonly used in the general population, the frequency of the co-occurrence can more precisely be studied in clinical samples. We provide the most recent literature results on the association of SUDs and anxiety, and evidence for one explicative model or the other when available. For substances with sedative properties (alcohol, benzodiazepines, cannabis, opioids), both evidence for a self-medication and for a toxic effect exist. For substances with psychostimulant properties (tobacco, cocaine, and amphetamines), the literature favors the toxic hypothesis to explain the association with anxiety disorders. We give practical steps for the recognition of these dual diagnoses and present therapeutic issues, although the strategies are rarely evidence based.

Entities:  

Mesh:

Year:  2015        PMID: 25617040     DOI: 10.1007/s11920-014-0544-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  46 in total

Review 1.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

Review 2.  Cannabis use disorder: epidemiology and management.

Authors:  Jan Copeland; Wendy Swift
Journal:  Int Rev Psychiatry       Date:  2009-04

Review 3.  Monitoring of socio-economic inequalities in smoking: learning from the experiences of recent scientific studies.

Authors:  M M Schaap; A E Kunst
Journal:  Public Health       Date:  2009-01-14       Impact factor: 2.427

4.  Illicit drug use and anxiety disorders: findings from two community surveys.

Authors:  Jitender Sareen; Mariette Chartier; Martin P Paulus; Murray B Stein
Journal:  Psychiatry Res       Date:  2006-05-19       Impact factor: 3.222

5.  Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions.

Authors:  S S Martins; M C Fenton; K M Keyes; C Blanco; H Zhu; C L Storr
Journal:  Psychol Med       Date:  2011-10-17       Impact factor: 7.723

6.  Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity.

Authors:  Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-05-08       Impact factor: 3.829

7.  Smoking and mental illness: results from population surveys in Australia and the United States.

Authors:  David Lawrence; Francis Mitrou; Stephen R Zubrick
Journal:  BMC Public Health       Date:  2009-08-07       Impact factor: 3.295

8.  National trends in the office-based prescription of schedule II opioids.

Authors:  Mark Olfson; Shuai Wang; Miren Iza; Stephen Crystal; Carlos Blanco
Journal:  J Clin Psychiatry       Date:  2013-09       Impact factor: 4.384

9.  Does Posttraumatic Stress Disorder (PTSD) Affect Post-Treatment Methamphetamine Use?

Authors:  Suzette Glasner-Edwards; Larissa J Mooney; Alfonso Ang; Maureen Hillhouse; Richard Rawson
Journal:  J Dual Diagn       Date:  2013-04-01

10.  Patterns of benzodiazepine use in a Canadian population sample.

Authors:  Eleonora Esposito; Corrado Barbui; Scott B Patten
Journal:  Epidemiol Psichiatr Soc       Date:  2009 Jul-Sep
View more
  41 in total

1.  Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.

Authors:  Robert W Gould; Russell J Amato; Michael Bubser; Max E Joffe; Michael T Nedelcovych; Analisa D Thompson; Hilary H Nickols; Johannes P Yuh; Xiaoyan Zhan; Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Frank W Byers; Jerri M Rook; John S Daniels; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2015-08-28       Impact factor: 7.853

2.  Behavioral Sleep-Related Problems in Clinically Anxious Children: A Parent-Report Diary Study.

Authors:  Therese E Price; Lara J Farrell; Caroline L Donovan; Allison M Waters
Journal:  Child Psychiatry Hum Dev       Date:  2019-10

Review 3.  Anxiety and Nicotine Dependence: Emerging Role of the Habenulo-Interpeduncular Axis.

Authors:  Susanna Molas; Steven R DeGroot; Rubing Zhao-Shea; Andrew R Tapper
Journal:  Trends Pharmacol Sci       Date:  2016-11-24       Impact factor: 14.819

4.  Cannabis Use and Prospective Long-Term Association with Anxiety: A Systematic Review and Meta-Analysis of Longitudinal Studies: Usage du cannabis et association prospective à long terme avec l'anxiété: une revue systématique et une méta-analyse d'études longitudinales.

Authors:  Siqi Xue; M Ishrat Husain; Haoyu Zhao; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2020-09-10       Impact factor: 4.356

5.  Overexpression of the Histone Dimethyltransferase G9a in Nucleus Accumbens Shell Increases Cocaine Self-Administration, Stress-Induced Reinstatement, and Anxiety.

Authors:  Ethan M Anderson; Erin B Larson; Daniel Guzman; Anne Marie Wissman; Rachael L Neve; Eric J Nestler; David W Self
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  Buspirone reduces sexual risk-taking intent but not cocaine self-administration.

Authors:  B Levi Bolin; Joshua A Lile; Katherine R Marks; Joshua S Beckmann; Craig R Rush; William W Stoops
Journal:  Exp Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.157

8.  A longitudinal analysis of cannabis use and mental health symptoms among gay, bisexual, and other men who have sex with men in Vancouver, Canada.

Authors:  Frank Y Chou; Heather L Armstrong; Lu Wang; Nicanor Bacani; Nathan J Lachowsky; Thomas L Patterson; Zach Walsh; Gbolahan Olarewaju; Kiffer G Card; Eric A Roth; Robert S Hogg; David M Moore
Journal:  J Affect Disord       Date:  2019-01-15       Impact factor: 4.839

Review 9.  The Negative Affect of Protracted Opioid Abstinence: Progress and Perspectives From Rodent Models.

Authors:  Lola Welsch; Julie Bailly; Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Biol Psychiatry       Date:  2019-08-06       Impact factor: 13.382

10.  Knockdown of the histone di-methyltransferase G9a in nucleus accumbens shell decreases cocaine self-administration, stress-induced reinstatement, and anxiety.

Authors:  Ethan M Anderson; Haosheng Sun; Daniel Guzman; Makoto Taniguchi; Christopher W Cowan; Ian Maze; Eric J Nestler; David W Self
Journal:  Neuropsychopharmacology       Date:  2018-12-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.